2.18
+0.33(+17.84%)
Currency In USD
| Previous Close | 1.85 |
| Open | 1.82 |
| Day High | 2.2 |
| Day Low | 1.82 |
| 52-Week High | 28.6 |
| 52-Week Low | 1.66 |
| Volume | 86,720 |
| Average Volume | 183,864 |
| Market Cap | 1.54M |
| PE | -0.12 |
| EPS | -18.93 |
| Moving Average 50 Days | 4.57 |
| Moving Average 200 Days | 7.22 |
| Change | 0.33 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $5.21 as of November 08, 2025 at a share price of $2.18. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 5 years ago, it would be worth $46.11 as of November 08, 2025 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPsSOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-sign
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derma
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
GlobeNewswire Inc.
Oct 15, 2025 1:15 PM GMT
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treate